31865-25-5 Usage
General Description
6-Oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid, phenylmethyl ester is a chemical compound that is a derivative of the bicyclic compound known as 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid. 6-Oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid, phenylmethyl ester is commonly used as a precursor in the synthesis of pharmaceuticals and organic compounds. It is also used as a building block in the production of various chemical compounds. 6-Oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid, phenylmethyl ester is a colorless, odorless substance that is soluble in organic solvents and has a wide range of applications in the field of chemistry and pharmaceuticals. It is important to handle this compound with care, as it can be toxic if ingested or inhaled, and can cause irritation to the skin and eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 31865-25-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,8,6 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 31865-25:
(7*3)+(6*1)+(5*8)+(4*6)+(3*5)+(2*2)+(1*5)=115
115 % 10 = 5
So 31865-25-5 is a valid CAS Registry Number.
31865-25-5Relevant articles and documents
JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE
-
, (2022/01/24)
-
SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF
-
Paragraph 0740-0741, (2020/12/25)
The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
-
Paragraph 00452; 00457, (2019/08/29)
The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
